Compare IDEXX Laboratories, Inc. (IDXX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Match Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $572.77 (market cap $46.22B), while Match Group Inc trades at $36.5 (market cap $8.45B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.5× Match Group Inc's market cap, and Match Group Inc pays a 2.17% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MTCH | |
|---|---|---|
Market Cap | $46.22B | $8.45B |
Sector | Health | Media |
52-Week High | $766.68 | $41.24 |
52-Week Low | $526.44 | $28.90 |
Enterprise Value | $47.12B | $11.42B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Match Group (MTCH) trades at $36.36, down 1.01% on the day, with a bearish technical signal but neutral oscillators. The company reported mixed Q2 2026 results, missing revenue estimates but beating EPS, with Tinder showing engagement improvements and Hinge growing revenue 22% year-over-year. Financials indicate strong profitability with a net income margin of 20.17% and a P/E ratio of 13.05, while cash flow trends show positive net cash flow in 2025. Recent news highlights institutional buying and Zacks rankings for growth, income, and value stocks.
The outlook for MTCH is cautiously optimistic, with analyst consensus pointing to a $42.33 price target and no sell ratings. Risks include Tinder's sluggish performance and high debt levels, but opportunities lie in Hinge's expansion and product innovation. Investors should weigh solid fundamentals against competitive and execution risks in the dating app market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
